1. Home
  2. ONTF vs AKBA Comparison

ONTF vs AKBA Comparison

Compare ONTF & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ON24 Inc.

ONTF

ON24 Inc.

HOLD

Current Price

$8.11

Market Cap

347.2M

Sector

Technology

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.16

Market Cap

375.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONTF
AKBA
Founded
1998
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
347.2M
375.0M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
ONTF
AKBA
Price
$8.11
$1.16
Analyst Decision
Hold
Strong Buy
Analyst Count
2
3
Target Price
$8.10
$4.67
AVG Volume (30 Days)
986.7K
2.7M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
32.67
93.94
EPS
N/A
N/A
Revenue
$139,312,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.70
$1.13
52 Week High
$8.11
$4.08

Technical Indicators

Market Signals
Indicator
ONTF
AKBA
Relative Strength Index (RSI) 67.87 34.82
Support Level $7.84 $1.16
Resistance Level N/A $1.56
Average True Range (ATR) 0.02 0.07
MACD -0.01 -0.03
Stochastic Oscillator 88.89 12.05

Price Performance

Historical Comparison
ONTF
AKBA

About ONTF ON24 Inc.

ON24 Inc provides a cloud-based intelligent engagement platform that combines experiences with personalization and content, to enable sales and marketing organizations to capture and act on connected insights at scale. The company's platform offers a portfolio of interactive and hyper-personalized digital experience products that create and capture actionable, real-time data at scale from millions of professionals to provide businesses with buying signals and behavioral insights to efficiently convert prospects into customers. It provides solutions to Financial services, Life Sciences, Life sciences, Insurance, Technology, Associations, and Others. Geographically, the company derives maximum revenue from United States, and also has its presence in EMEA and Other Countries.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: